Carbapenem-resistant enterobacteriaceae: An emerging threat

U.S. Pharmacist

Volumn 38, Issue 12, 2013, Pages

  El Srougy, Radwa ^a   Kalabalik, Julie ^b   Kim, Chloe ^c   Song, Ashley ^c  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; COLISTIN; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MEROPENEM; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; BACTERIUM CARRIER; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BROTH DILUTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE INFECTION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE INFECTION; CLINICAL FEATURE; CROSS RESISTANCE; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE MUTATION; HAND WASHING; HEALTH CARE PERSONNEL MANAGEMENT; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; KLEBSIELLA; KLEBSIELLA PNEUMONIAE INFECTION; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL DEVICE; MEROPENEM RESISTANT KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MODIFIED HODGE TEST; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHARMACIST; POLYPHARMACY; PROTEUS; PSEUDOMONAS AERUGINOSA; SCREENING TEST; STAFF TRAINING; SYSTEMATIC REVIEW (TOPIC);

EID: 84891062717     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (49)

1. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008; 29: 1099-1106.
2. Schwaber MJ, Lev B, Israeli A, et al. Containment of a countrywide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011; 52: 848-855.
3. Chitnis A, Caruthers P, Rao A, et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hospitl Epidem. 2012; 33: 984-992.
4. CDC. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013; 62: 165-170.
5. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009; 65: 414-426.
6. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29: 996-1011.
7. Bradford PA, Urban C, Mariano N, et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother. 1997; 41: 563-569.
8. Mackenzie FM, Forbes KJ, Dorai-John T, et al. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet. 1997; 350: 783.
9. Gupta N, Limbago BM, Patel JB, et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011; 53: 60-67.
10. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol. 2007; 45: 2723-2725.
11. Hussein K, Sprecher H, Mashiach T, et al. Carbapenem resistance among Klebsiella pneumoniae ioslates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009; 30: 666-671.
12. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumonia infections: a matched case-control study. J Antimicrob Chemother. 2007; 60: 1124-1130.
13. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008; 52: 1028-1033.
14. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother. 2010; 65: 1807-1818.
15. Ben-David D, Masarwa S, Navon-Venezia S, et al; Israel PACF CRKP (Post-Acute-Care Facility Carbapenem-Resistant Klebsiella pneumoniae) Working Group. Carbapenem-resistant Klebsiella pneumoniae in post-acute care facilities in Israel. Infect Control Hosp Epidemiol. 2011; 32: 845-853.
16. Debby BD. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization in an intensive care unit. Eur J Clin Microbiol Infect Dis. 2012; 31: 1811-1817.
17. Carbapenem-resistant Enterobacteriaceae (CRE) infection: clinician FAQs. National Center for Emerging and Zoonotic Infectious Diseases; CDC. www. cdc. gov/hai/organisms/cre/cre-clinicianFAQ. html. Accessed November 11, 2013.
18. Guidance for Control of Carbapenem-Resistant Enterobacteriaceae (CRE). 2012 CRE Toolkit. National Center for Emerging and Zoonotic Infectious Diseases; CDC. www. cdc. gov/hai/pdfs/cre/CRE-guidance-508. pdf. Accessed June 25, 2013.
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty Second Informational Supplement (January 2012). CLSI document M100-S22. Wayne, PA: CLSI; 2012.
20. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother. 2005; 49: 3018-3020.
21. Laboratory protocol for detection of carbapenem-resistant or carbapenemase-producing, Klebsiella spp. and E. coli from rectal swabs. Department of Health and Human Services; CDC. www. cdc. gov/hai/pdfs/labsettings/klebsiella_or_ecoli. pdf. Accessed July 1, 2013.
22. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013; 80: 225-233.
23. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011; 69: 357-362.
24. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005; 56: 128-132.
25. Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011; 37: 244-247.
26. Pankey GA, Ashcraft DS. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapanemase-producing Klebsiella pneumoniae. Diagn Microbial Infect Dis. 2011; 70: 561-564.
27. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012; 11: 32.
28. Samonis G, Matthaiou DK, Kofteridis D, et al. In vitro susceptibility to various antibiotics of colistin-resistant gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis. 2010; 50: 1689-1691.
29. Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol. 2009; 47: 1611-1612.
30. Castanheira M, Sader HS, Deshapnde LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2008; 52: 570-573.
31. Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008; 62: 895-904.
32. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis. 2009; 49: 271-274.
33. Daly MW, Riddle DJ, Ledeboer NA, et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy. 2007; 27: 1052-1057.
34. Goldfarb D, Harvey SB, Jessamine K, et al. Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission. J Clin Microbiol. 2009; 47: 1920-1922.
35. David van Duin, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diag Microbiol Infect Dis. 2013; 75: 115-120.
36. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from the urine. Antimicrob Agents Chemother. 2011; 55: 5893-5899.
37. Petrosillo N, Giannella M, Lewis R, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae. Expert Rev Anti Infect Ther. 2013; 11: 159-177.
38. Benenson S, Navon-Venezia S, Carmeli Y, et al. Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult: successful treatment with gentamicin and colistin. Int J Infect Dis. 2009; 13e: 295-e298.
39. Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbanemase KPC-2 in Brooklyn, New York. Clin Infect Dis. 2007; 44: 972-975.
40. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010; 54: 4112-4115.
41. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement (June 2010 update). CLSI document M100-S20-U. Wayne, PA: CLSI; 2010.
42. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56: 2108-2113.
43. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55: 943-950.
44. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs); an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010; 65: 1119-1125.
45. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2010; 54: 2732-2734.
46. Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant and extensively drug-resistant Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010; 35: 240-243.
47. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010; 50: 364-373.
48. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 2010; 31: 620-626.
49. Management of multidrug-resistant organisms in healthcare settings, 2006. CDC. www. cdc. gov/hicpac/pdf/guidelines/MDROGuideline2006. pdf. Accessed June 25, 2013.